abstract |
The present invention relates to positive allosteric modulators ("PAMs") comprising metabotropic glutamatergic receptor subtype 2 ("mGluR2") or pharmaceutically acceptable salts or solvates thereof, or metabotropic glutamatergic receptors A combination of an agonist compound of receptor subtype 2, or a pharmaceutically acceptable salt or solvate thereof, and a synaptic vesicle protein 2A ("SV2A") ligand. |